ALK and non-small cell lung carcinoma: For several decades, the primary systemic treatment of advanced NSCLC remained chemotherapy until the advent of tyrosine kinase inhibitor (TKI) therapy following the discovery of several driver mutations such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS1.